Circadian clocks are endogenous molecular time-keeping systems that underlie daily fluctuations in multiple physiological and biochemical processes. It is now well recognized that dysfunction of the circadian system may be associated with a heightened incidence of cancer. This brief review presents evidence supporting the important role played by circadian clocks in the development of cancer and the therapeutic efficacy of anticancer agents. A number of circadian clock genes have been identified, which include transcription factors that regulate gene expression. Continued research in this area should increase understanding of the role of circadian clocks which could, ultimately, reduce the incidence of cancer in people with disrupted sleep-wake cycles, such as 24-h shift workers and flight attendants, and provide optimal chronopharmacology for cancer treatment.
Introduction
The physiological and behavioural activities of many organisms are driven by the daily light-dark cycles of the Earth. These temporal activities are often referred to as the circadian clocks, which form the endogenous timing that persists in the absence of external cues. 1 Mammalian circadian clocks are generated by a master pacemaker located in the suprachiasmatic nuclei (SCN) of the anterior hypothalamus. 2 Endogenous, self-sustained, 24-h rhythmic oscillations within the SCN are entrained by light acting on photoreceptors in the eyes, which is then transmitted via the retinohypothalamic tract to the SCN. In turn, the SCN synchronizes other clocks throughout the body by regulating neural and hormonal signals. 3, 4 Over the past decade, considerable progress has been made in elucidating the molecular basis of circadian rhythms in mammals. At the molecular level, the rhythms of the circadian clocks are controlled by the interaction between positive and negative feedback loops consisting of key clock regulators. 1,5 A model encompassing a feedback system involving heterodimer transcriptional factors (circadian locomotor output cycles kaput [CLOCK] and brain and muscle aryl hydrocarbon receptor nuclear translocatorlike 1 [BMAL1]), cryptochromes 1 and 2 (CRY1 and CRY2), and three Period (mPER1, a X-L Huang and C-J Fu contributed equally to this work. X-L Huang, C-J Fu, R-F Bu Circadian clocks in cancer development and treatment mPER2, and mPER3) regulators has been widely described. 6 Many key circadian regulators contain the 'Period-Arnt-Single minded' (PAS) domain in their amino acid sequences. 7 In addition, both the CLOCK and BMAL1 genes contain a DNA-binding region consisting of a basic helix-loop-helix. 6 The CLOCK/BMAL1 heterodimer activates transcription by binding to the E-box element in the promoter region of its target genes. 7 Among the target genes of the CLOCK/BMAL1 heterodimer are the PERIOD and CRY genes. 7 In turn, CRY1 and CRY2 act as potent negative regulators that inhibit the transcriptional activity of the CLOCK/ BMAL1 heterodimer. 7 Transcription of the BMAL1 gene is further regulated by two orphan nuclear receptors, Rev-Erbα and retinoic acid receptor-related orphan receptor α (RORα). 8 These orphan nuclear receptors exert opposing influences on the transcriptional activity of the BMAL1 gene by binding to the ROR-response elements in the promoter. 7 Post-translational phosphorylation plays an important role in the generation of circadian rhythms and casein kinase Iε, a serine/threonine kinase, is an important player in the phosphorylation of key clock proteins. 9 The misalignment of circadian rhythms in physiology, endocrinology, metabolism and behavioural rhythms with the external environment is common among humans who work night shifts or routinely travel across multiple time zones. There is increasing evidence linking chronic disruption of the sleep-wake cycle in humans with increased risk of certain cancers. For example, an increasing incidence of breast cancer has been observed among female flight attendants. 10, 11 Similarly, an increased risk of breast and endometrial cancer has been associated with rotating and/or permanent night shift work. 12, 13 These changes might merely be associated with lifestyle patterns that cause disruption to the biorhythms, but more persuasive data directly linking circadian disruptions and cancer have been found in rodents. For example, in mice inoculated with tumours after they were exposed to simulated chronic jet lag, which was achieved by exposing them to a 6-h phase advance or delay every week, survival was worse than in mice inoculated with tumours kept under normal light-dark cycles. 14 In addition to its association with higher cancer incidence, circadian disruption has been shown to be associated with faster tumour growth in experimental models 14 and with shorter survival times in clinical studies. 15 This review will focus on the circadian clock genes, which, by being closely associated with tumourigenesis by controlling cell cycle, DNA repair, apoptosis and drug metabolism, might become potential targets for chronopharmacology in the treatment of cancer.
Circadian genes and tumourigenesis
A number of polymorphisms in the human clock genes PER2, PER3, CLOCK and aralkylamine N-acetyltransferase have been reported as alleles that could be subject to selection, and the neuronal PAS domain protein 2 (NPAS2) polymorphism is associated with risk of non-Hodgkin's lymphoma and breast cancer. 12, 15 Similarly, after treatment with ionizing radiation, mPER2
gene-deficient mutant mice developed spontaneous lymphoma at an accelerated rate compared with wild-type mice. 16 Circadian proteins PER1 and PER2 are linked to DNA damage signalling, and overexpression of either the PER1 or PER2 genes in cancer cells inhibit their neoplastic X-L Huang, C-J Fu, R-F Bu Circadian clocks in cancer development and treatment growth and increase their apoptotic rate. 17 Importantly, recognition that PER1 and PER2 are involved in ataxia telangiectasia mutated-checkpoint kinase DNA damage response pathways implicates the circadian system's participation in tumour suppression. 18 Evidence shows that the activity of the BMAL1 promoter is enhanced during DNA damage. 19 The discovery of the conservation of the DNA damage-mediated response of circadian clocks from lower eukaryotes to mammals suggests that clock resetting is a universal property of DNA damage, and supports the concept that DNA repair is intimately linked to circadian rhythm. 19 
Circadian clocks and cancer therapeutics
Cell-cycle events are co-ordinated along the 24-h period in healthy bone marrow, gut and skin, which are three frequent targets for the toxicity of cancer treatments. The proportions of S-and G 2 /M-phase cells increase by approximately 50% in the second half of the dark phase of the lightdark cycle, whereas G 0 /G 1 cells predominate during the light phase in the total bone marrow of male B6D2F1 mice. 20 In this tissue, Bcl-2 protein levels triple over the 24h period, with a maximum levels being reached at early light. 20 An opposite pattern characterizes the proapoptotic protein BAX, which has a five-fold 24-h change and a peak at Zeitgeber time 15. 20 The temporary arrest of cycling cells in G 0 /G 1 , and the high Bcl-2 and low BAX levels during the light span when mice rest, help to explain the best circadian timing for the tolerability of cancer treatments such as irinotecan and docetaxel in male B6D2F1 mice. 21, 22 The circadian control of drug metabolism and detoxification also profoundly modifies cell exposure to these medications, whose molecular targets are usually clock regulated. 23 For example, the increased detoxification of 5-FU during the light span results from the circadian peak in dihydropyrimidine dehydrogenase activity in liver and other healthy cells. 23 The outcome is reduced proportions of S-phase cells in bone marrow, gut and skin, as a mechanism for improved circadian tolerability. 24 Both the transcription and activity of thymidylate synthetase (TS), which produces a unique de novo source of thymidylate, are linked to the early S-phase in proliferating tissues. 25 Consistently, bone marrow TS activity peaks near the mid-dark phase and this coincides with the greatest haematological toxicity of 5-FU in female CD2F1 mice. 23 Whereas circadian phase I and II metabolism partly determine irinotecan pharmacology over the 24-h period, topoisomerase I (Topo I; the main protein target of this drug) is mostly active during the late S-phase. 4 Thus, the circadian gating of the cell cycle and, possibly, the direct control of Topo I by the molecular clock contribute to better haematological tolerability of irinotecan during the rest span of male ICR mice.
How is this new knowledge being applied clinically? The most exciting avenue is the development of chronotherapy for cancer: using medications at times when they will be most effective on cancer cells, while simultaneously minimizing side-effects. 27 Circadian dosing time influences the extent of toxicity of more than 30 anticancer drugs and it has been shown in animal models that the survival rate varies by at least 50% depending on when a 'lethal dose' of drug is given. 4 Maybe the reason is that cellular repair mechanisms, such as nucleotide excision, are subject to circadian regulation and many key genes are associated with xenobiotic metabolism and transport. 28 • Received for publication 25 April 2011 • Accepted subject to revision 28 April 2011
• Revised accepted 8 October 2011 Copyright © 2011 Field House Publishing LLP More strikingly, the administration of a drug at a circadian time when it is best tolerated usually achieves the best anticancer activity. 29 This knowledge is being applied more and more frequently in clinical trials. For example, Giacchetti et al. 30 conducted a phase III trial comparing 'chronomodulated' administration of 5-FU, leucovorin and oxaliplatin against the standard regimen in patients with newly diagnosed metastatic colorectal cancer. There was a significant survival advantage with the chronomodulated regimen, but it was confined to men, whereas women fared better on the standard regimen, highlighting the need for further studies. 30 Moreover, rodent studies using the drug seliciclib, a cyclin-dependent kinase inhibitor, showed that drug treatment during the subjective day reduced tumour growth by > 50% compared with the subjective night, and that this increased reduction apparently resulted from the restoration of normally phased CLOCK gene expression patterns in the tumours. 31
Circadian clocks and cancer prognosis
Another potential determinant of patient outcome lies in the molecular clock in the host and tumour. Thus, in mice, the clock genes, CLOCK and BMAL1, as well as the clock-controlled transcription factors (albumin D-binding protein [DBP], transcription enhancer factor [TEF] and homing endonuclease-like function [HEF]) have been found to control average and/or rhythmic tolerability to the alkylating agent, cyclophosphamide, and the topoisomerase II inhibitor mitoxantrone. 32, 33 Furthermore, clock gene expression seems to be altered in some, but not all, human cancers compared with healthy corresponding tissues, possibly as a result of promoter methylation. 14, 34 Thus, the identification of deregulated CLOCK and/or CLOCK-controlled pathways in host and malignant cells could elicit the development of novel tumour-based approaches to cancer chronotherapeutics.
Circadian rhythm is regarded as a prognostic indicator of survival. Many studies indicate that patients with metastatic colorectal or breast cancer may display circadian rhythm abnormalities, which either reflect aggressive disease or contribute to disease prognosis via mechanisms that need to be explored further. 4 These studies suggest that altered circadian clocks may contribute to the acceleration of cancer growth. 14 Another study has shown that hormonal circadian rhythms were altered in women at high risk of breast cancer compared with women at low risk of this disease. 35 
Conclusions
Research suggests that circadian clocks play an important role in cancer prevention and chemotherapy. Well-designed clinical and laboratory studies should be performed to identify polymorphisms of CLOCK genes among 24-h shift workers, to be able to prevent cancer at an earlier stage and to provide novel chronopharmacological regimens to optimize cancer chemotherapy and improve prognosis.
